Many US Food and Drug Administration user fees for drugs and biosimilars increased for fiscal year 2023, with a few notable exceptions.
The agency announced the new prescription drug, generic drug, biosimilar and priority review voucher fees on...
US FDA's FY 2023 User Fees Finally Revealed
Listen to this article
Several fees for prescription drug, generic drug, and biosimilar applications are set to increase, although some also will drop.
Learn what's happening at the US FDA. On the go.
More from User Fees
• By
Exploring How Everyday Industrial Compounds Enter Our Systems, Their Health Implications, and the Ongoing Quest for Safer Alternatives .
• By
The agency’s plan for advanced manufacturing seeks more harmonization, while also seeking to codify internal practices with guidance and training.
• By
Pink Sheet infographic shows that while overall growth continues at the drugs and biologics centers, the US FDA still must add many employees to meet user fee-mandated hiring goals.
• By
A lack of process documentation was part of the reason the FDA forgot to account for fee refunds in its estimates of incoming applications for two fiscal years, a mistake that likely cost the agency millions in revenue.
More from Pathways & Standards
• By
Brazil has also published its recent regulatory reliance regulations in English, a move designed to increase confidence in its decisions as it presses on with aligning its national practices with global best practices.
• By
The US FDA commissioner also said the hub is looking for an executive director who will work with the CBER and CDER heads, who will serve as co-leads.
• By
The FDA and sponsors of two new accelerated approval drugs for PBC have taken steps in study design, initiation and reporting transparency to ensure timely completion; Intercept’s COBALT trial of obeticholic acid was negatively impacted by product safety labeling changes and a high crossover rate to commercial drug.